The major human apurinic/apyrimidinic endonuclease APE1 plays a pivotal role in the repair of base damage via participation in the DNA base excision repair (BER) pathway. Increased activity of APE1, often observed in tumor cells, is thought to contribute to resistance to various anticancer drugs, whereas down-regulation of APE1 sensitizes cells to DNA damaging agents. Thus, inhibiting APE1 repair endonuclease function in cancer cells is considered a promising strategy to overcome therapeutic agent resistance. Despite ongoing efforts, inhibitors of APE1 with adequate drug-like properties have yet to be discovered. Using a kinetic fluorescence assay, we conducted a fully-automated high-throughput screen (HTS) of the NIH Molecular Libraries Small Molecule Repository (MLSMR), as well as additional public collections, with each compound tested as a 7-concentration series in a 4 μL reaction volume. Actives identified from the screen were subjected to a panel of confirmatory and counterscreen tests. Several active molecules were identified that inhibited APE1 in two independent assay formats and exhibited potentiation of the genotoxic effect of methyl methanesulfonate with a concomitant increase in AP sites, a hallmark of intracellular APE1 inhibition; a number of these chemotypes could be good starting points for further medicinal chemistry optimization. To our knowledge, this represents the largest-scale HTS to identify inhibitors of APE1, and provides a key first step in the development of novel agents targeting BER for cancer treatment.
References
[1]
Bapat A, Fishel M, Kelley MR (2009) Going Ape as an Approach to Cancer Therapeutics. Antioxid Redox Signal 11: 651–668.
[2]
Kulkarni A, Wilson DM 3rd (2008) The involvement of DNA-damage and -repair defects in neurological dysfunction. Am J Hum Genet 82: 539–566.
[3]
Fortini P, Pascucci B, Parlanti E, D'Errico M, Simonelli V, et al. (2003) The base excision repair: mechanisms and its relevance for cancer susceptibility. Biochimie 85: 1053–1071.
[4]
Abbotts R, Madhusudan S (2010) Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Cancer Treat Rev 36: 425–435.
[5]
Barnes DE, Lindahl T (2004) Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu Rev Genet 38: 445–476.
[6]
Karran P, Offman J, Bignami M (2003) Human mismatch repair, drug-induced DNA damage, and secondary cancer. Biochimie 85: 1149–1160.
[7]
Cleaver JE (2005) Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat Rev Cancer 5: 564–573.
[8]
Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8: 193–204.
[9]
Powell SN, Bindra RS (2009) Targeting the DNA damage response for cancer therapy. DNA Repair (Amst) 8: 1153–1165.
[10]
Sharma RA, Dianov GL (2007) Targeting base excision repair to improve cancer therapies. Mol Aspects Med 28: 345–374.
[11]
Wilson DM 3rd, Barsky D (2001) The major human abasic endonuclease: formation, consequences and repair of abasic lesions in DNA. Mutat Res 485: 283–307.
[12]
Fung H, Demple B (2005) A vital role for Ape1/Ref1 protein in repairing spontaneous DNA damage in human cells. Mol Cell 17: 463–470.
[13]
Izumi T, Brown DB, Naidu CV, Bhakat KK, Macinnes MA, et al. (2005) Two essential but distinct functions of the mammalian abasic endonuclease. Proc Natl Acad Sci U S A 102: 5739–5743.
[14]
Fishel ML, Kelley MR (2007) The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. Mol Aspects Med 28: 375–395.
[15]
McNeill DR, Wilson DM 3rd (2007) A dominant-negative form of the major human abasic endonuclease enhances cellular sensitivity to laboratory and clinical DNA-damaging agents. Mol Cancer Res 5: 61–70.
[16]
McNeill DR, Lam W, DeWeese TL, Cheng YC, Wilson DM, 3rd (2009) Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites. Mol Cancer Res 7: 897–906.
[17]
Ashworth A (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26: 3785–3790.
[18]
Sultana R, McNeill DR, Abbotts R, Mohammed MZ, Zdzienicka MZ, et al.. (2012) Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. Int J Cancer in press: n/a-n/a.
[19]
Madhusudan S, Smart F, Shrimpton P, Parsons JL, Gardiner L, et al. (2005) Isolation of a small molecule inhibitor of DNA base excision repair. Nucleic Acids Res 33: 4711–4724.
[20]
Seiple LA, Cardellina JH 2nd, Akee R, Stivers JT (2008) Potent inhibition of human apurinic/apyrimidinic endonuclease 1 by arylstibonic acids. Mol Pharmacol 73: 669–677.
[21]
Simeonov A, Kulkarni A, Dorjsuren D, Jadhav A, Shen M, et al. (2009) Identification and characterization of inhibitors of human apurinic/apyrimidinic endonuclease APE1. PLoS ONE 4: e5740.
[22]
Zawahir Z, Dayam R, Deng J, Pereira C, Neamati N (2009) Pharmacophore guided discovery of small-molecule human apurinic/apyrimidinic endonuclease 1 inhibitors. J Med Chem 52: 20–32.
[23]
Bapat A, Glass LS, Luo M, Fishel ML, Long EC, et al. (2010) Novel small molecule inhibitor of Ape1 endonuclease blocks proliferation and reduces viability of glioblastoma cells. J Pharmacol Exp Ther 334: 988–998.
[24]
Wilson III DM, Simeonov A (2010) Small molecule inhibitors of DNA repair nuclease activities of APE1. Cell Mol Life Sci 67: 3621–3631.
[25]
Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, et al. (2006) Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A 103: 11473–11478.
[26]
Yasgar A, Shinn P, Jadhav A, Auld D, Michael S, et al. (2008) Compound Management for Quantitative High-Throughput Screening. JALA Charlottesv Va 13: 79–89.
[27]
Inglese J, Johnson RL, Simeonov A, Xia M, Zheng W, et al. (2007) High-throughput screening assays for the identification of chemical probes. Nat Chem Biol 3: 466–479.
[28]
Michael S, Auld D, Klumpp C, Jadhav A, Zheng W, et al. (2008) A robotic platform for quantitative high-throughput screening. Assay Drug Dev Technol 6: 637–657.
[29]
Hill AV (1910) The possible effects of the aggregation of the molecule of haemoglobin on its dissociation curves. J Physiol(London). 4–7.
[30]
Roberts G, Myatt GJ, Johnson WP, Cross KP, Blower PE Jr (2000) LeadScope: software for exploring large sets of screening data. J Chem Inf Comput Sci 40: 1302–1314.
[31]
Wilson DM, 3rd, Takeshita M, Grollman AP, Demple B (1995) Incision activity of human apurinic endonuclease (Ape) at abasic site analogs in DNA. J Biol Chem 270: 16002–16007.
[32]
Wilson DM, 3rd (2005) Ape1 abasic endonuclease activity is regulated by magnesium and potassium concentrations and is robust on alternative DNA structures. J Mol Biol 345: 1003–1014.
[33]
Zhang JH, Chung TD, Oldenburg KR (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67–73.
[34]
Eastwood BJ, Farmen MW, Iversen PW, Craft TJ, Smallwood JK, et al. (2006) The Minimum Significant Ratio: A Statistical Parameter to Characterize the Reproducibility of Potency Estimates from Concentration-Response Assays and Estimation by Replicate-Experiment Studies. J Biomol Screen 11: 253–261.
[35]
Jadhav A, Ferreira R, Klumpp C, Mott BT, Austin C, et al. (2010) Quantitative Analyses of Aggregation, Autofluorescence, and Reactivity Artifacts in a Screen for Inhibitors of a Thiol Protease J Med Chem. 53: 37–51.
[36]
Erzberger JP, Barsky D, Scharer OD, Colvin ME, Wilson DM 3rd (1998) Elements in abasic site recognition by the major human and Escherichia coli apurinic/apyrimidinic endonucleases. Nucl Acids Res 26: 2771–2778.
[37]
Mol CD, Hosfield DJ, Tainer JA (2000) Abasic site recognition by two apurinic/apyrimidinic endonuclease families in DNA base excision repair: the 3' ends justify the means. Mutat Res 460: 211–229.
[38]
Heyduk T, Heyduk E (2002) Molecular beacons for detecting DNA binding proteins. Nat Biotechnol 20: 171–176.
[39]
Lea WL, Simeonov A (2011) Fluorescence Polarization Assays in Small Molecule Screening. Expert Op Drug Disc 6: 17–32.
[40]
Wyatt MD, Pittman DL (2006) Methylating agents and DNA repair responses: Methylated bases and sources of strand breaks. Chem Res Toxicol 19: 1580–1594.
[41]
Chou T-C (2006) Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. Pharmacological Reviews 58: 621–681.
[42]
Auparakkitanon S, Chapoomram S, Kuaha K, Chirachariyavej T, Wilairat P (2006) Targeting of hematin by the antimalarial pyronaridine. Antimicrob Agents Chemother 50: 2197–2200.
[43]
Naidu MD, Agarwal R, Pena LA, Cunha L, Mezei M, et al. (2011) Lucanthone and Its Derivative Hycanthone Inhibit Apurinic Endonuclease-1 (APE1) by Direct Protein Binding. PLoS ONE 6: e23679.
[44]
Shimozono N, Wada H, Biotech S (2004) Substituted Isoxazole Alkylamine Derivative and Agri- and Horticultural Fungicide. WO/2003/074501.
[45]
Rai G, Vyjayanti VN, Dorjsuren D, Simeonov A, Jadhav A, et al. (2012) Synthesis, Biological Evaluation, and Structure-Activity Relationships of a Novel Class of Apurinic/Apyrimidinic Endonuclease 1 Inhibitors. J Med Chem 55: 3101–3112.
[46]
Hong H, Neamati N, Winslow HE, Christensen JL, Orr A, et al. (1998) Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore. Antivir Chem Chemother 9: 461–472.
[47]
Hwang JS, Lee SA, Hong SS, Han XH, Lee C, et al. (2010) Phenanthrenes from Dendrobium nobile and their inhibition of the LPS-induced production of nitric oxide in macrophage RAW 264.7 cells. Bioorg Med Chem Lett 20: 3785–3787.
[48]
Sun W, Cama LD, Birzin ET, Warrier S, Locco L, et al. (2006) 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett 16: 1468–1472.
[49]
Bowers EM, Yan G, Mukherjee C, Orry A, Wang L, et al. (2010) Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol 17: 471–482.
[50]
Wang L, Gural A, Sun XJ, Zhao X, Perna F, et al. (2011) The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 333: 765–769.
[51]
Walensky LD, Stewart ML, Cohen N, Institute D-FCR (2011) Small Molecules for the Modulation of MCL-1 and Methods for Modulating Cell Death, Cell Division, Cell Differentiation, and Methods of Treating Disorders. WPO, WO/2011/094708.
[52]
Xia G, Benmohamed R, Kim J, Arvanites AC, Morimoto RI, et al. (2011) Pyrimidine-2,4,6-trione Derivatives and Their Inhibition of Mutant SOD1-Dependent Protein Aggregation. Toward a Treatment for Amyotrophic Lateral Sclerosis. J Med Chem 54: 2409–2421.
[53]
Screpanti E, Santaguida S, Nguyen T, Silvestri R, Gussio R, et al. (2010) A Screen for Kinetochore-Microtubule Interaction Inhibitors Identifies Novel Antitubulin Compounds. PLoS ONE 5: e11603.
[54]
Rishton GM (1997) Reactive compounds and in vitro false positives in HTS. Drug Discovery Today 2: 382–384.
